A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.

PubWeight™: 1.13‹?› | Rank: Top 10%

🔗 View Article (PMID 16035063)

Published in Liver Transpl on August 01, 2005

Authors

Gary L Davis1, David R Nelson, Norah Terrault, Timothy L Pruett, Thomas D Schiano, Courtney V Fletcher, Christine V Sapan, Laura N Riser, Yufeng Li, Richard J Whitley, John W Gnann, Collaborative Antiviral Study Group

Author Affiliations

1: Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA. garydav@baylorhealth.edu

Associated clinical trials:

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. | NCT01804829

Articles citing this

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09

Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66

Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol (2006) 1.18

Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13

Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11

The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07

New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol (2009) 1.05

Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One (2013) 1.03

Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology (2014) 0.93

New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91

Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87

Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87

How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85

Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84

New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83

Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl (2016) 0.80

Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79

Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79

Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. J Clin Transl Hepatol (2014) 0.78

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity. Hepatology (2015) 0.77

Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol (2010) 0.77

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol (2014) 0.76

Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl (2016) 0.76

Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. PLoS Pathog (2016) 0.75

Update on the Development of Anti-Viral Agents Against Hepatitis C. J Clin Transl Hepatol (2013) 0.75

Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75

Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. J Korean Med Sci (2015) 0.75

Articles by these authors

The Chlamydomonas genome reveals the evolution of key animal and plant functions. Science (2007) 11.15

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49

The Physcomitrella genome reveals evolutionary insights into the conquest of land by plants. Science (2007) 8.12

Practice guidelines for the management of bacterial meningitis. Clin Infect Dis (2004) 7.79

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29

Clinical practice. Herpes zoster. N Engl J Med (2002) 4.72

Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis (2008) 4.46

Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33

Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet (2010) 4.27

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94

Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med (2007) 3.92

Viral encephalitis: familiar infections and emerging pathogens. Lancet (2002) 3.80

The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2008) 3.79

Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med (2015) 3.75

The Ectocarpus genome and the independent evolution of multicellularity in brown algae. Nature (2010) 3.60

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (2013) 3.40

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr (2003) 3.38

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30

An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18

Genetic drift at expanding frontiers promotes gene segregation. Proc Natl Acad Sci U S A (2007) 3.14

The Selaginella genome identifies genetic changes associated with the evolution of vascular plants. Science (2011) 3.10

Orientation discrimination of single-stranded DNA inside the alpha-hemolysin membrane channel. Proc Natl Acad Sci U S A (2005) 3.06

Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett (2006) 3.06

The African coelacanth genome provides insights into tetrapod evolution. Nature (2013) 2.78

Virus shapes and buckling transitions in spherical shells. Phys Rev E Stat Nonlin Soft Matter Phys (2003) 2.74

Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl (2014) 2.71

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64

Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54

Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl (2013) 2.48

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48

Genomic analysis of detoxification genes in the mosquito Aedes aegypti. Insect Biochem Mol Biol (2007) 2.38

Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38

Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35

The genome of Nectria haematococca: contribution of supernumerary chromosomes to gene expansion. PLoS Genet (2009) 2.29

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26

An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23

Direct visualization of dislocation dynamics in grain-boundary scars. Nat Mater (2005) 2.22

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20

Gene surfing in expanding populations. Theor Popul Biol (2007) 2.19

The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 2.19

Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med (2011) 2.18

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther (2008) 2.17

Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med (2005) 2.12

Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08

Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08

Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 2.07

DNA unzipped under a constant force exhibits multiple metastable intermediates. Proc Natl Acad Sci U S A (2003) 2.06

Cost of Gram-negative resistance. Crit Care Med (2007) 2.05

Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med (2011) 2.04

Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01

A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01

Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis (2004) 2.00

Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg (2012) 2.00

TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. AJR Am J Roentgenol (2015) 1.99

Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study. Fertil Steril (2002) 1.97

Foldable structures and the natural design of pollen grains. Proc Natl Acad Sci U S A (2010) 1.97

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.94

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94

Single molecule statistics and the polynucleotide unzipping transition. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.94

Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90

Effects of preoperative skin preparation on postoperative wound infection rates: a prospective study of 3 skin preparation protocols. Infect Control Hosp Epidemiol (2009) 1.89

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87

Moving toward elimination of healthcare-associated infections: a call to action. Am J Infect Control (2010) 1.86

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85

A tripartite paternally methylated region within the Gpr1-Zdbf2 imprinted domain on mouse chromosome 1 identified by meDIP-on-chip. Nucleic Acids Res (2010) 1.83

C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet (2002) 1.80

Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.78

Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78

Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother (2011) 1.77

Sexual dysfunction in men undergoing infertility evaluation: a cohort observational study. Fertil Steril (2003) 1.76

Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med (2004) 1.73

Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J (2003) 1.71

Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol (2012) 1.69

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68

FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood (2008) 1.67

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66

Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril (2003) 1.66

Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.64

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63

Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 1.62

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61

Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60

Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant (2003) 1.60

Contact isolation in surgical patients: a barrier to care? Surgery (2003) 1.60

Genome of the long-living sacred lotus (Nelumbo nucifera Gaertn.). Genome Biol (2013) 1.59

Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol (2006) 1.59

Are HIV-infected patients candidates for liver transplantation? J Hepatol (2008) 1.59

A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med (2003) 1.58